Marker Therapeutics (MRKR) announced that the Company has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas, CPRIT, to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio